A sponsor developing a breakthrough oral therapy for adult lupus nephritis turned to Worldwide for Phase III pivotal trial delivery under highly demanding clinical research conditions. Worldwide navigated complex participant recruitment with an episodic, difficult-to-diagnose condition, responded swiftly when natural disasters disrupted study sites across multiple regions, and maintained the data integrity required for a pivotal regulatory submission – enabling the sponsor to become the first to receive FDA approval for an oral therapy in adult lupus nephritis.
Discover how Worldwide’s nephrology and autoimmune team achieved this pivotal submission and approval in our full case study.
